The Weekly Dose: Rising Cyclosporiasis Cases, Psychedelic Therapy Safety Monitoring, and New FDA Approvals

This week's episode of The Weekly Dose opens with a public health alert on cyclosporiasis, a parasitic gastrointestinal illness that has now surpassed 450 reported cases across 18 states, with Michigan accounting for more than 300 of them. While no single outbreak source has been identified, officials note the true case count is likely underreported. The segment highlights diagnostic challenges—routine stool cultures miss the parasite, requiring a specifically ordered modified acid-fast stain or PCR test—and reinforces the pharmacist's role in counseling patients on persistent watery diarrhea, produce washing, and hand hygiene.

Next, the KOL feature turns to psychedelic medicine. Aza Allsop, MD, PhD, of Yale and Howard Universities, discusses what safety infrastructure might look like as psychedelic therapies move toward mainstream clinical use following a recent executive order aimed at accelerating their development. Allsop proposes a REMS-style monitoring system to track treatment administration and prevent patients from receiving overlapping treatments at multiple centers, while emphasizing that institutional enthusiasm from schools like Stanford and Johns Hopkins must be paired with an equitable, safety-first approach.

The policy roundup covers 4 major regulatory developments: accelerated approval of atacicept-vymj (Trutakna) for IgA nephropathy, the first therapy targeting both BAFF and APRIL pathways; an expanded indication for Casgevy, now approved for children as young as 2 with sickle cell disease or transfusion-dependent beta-thalassemia; approval of Tregzi, the first cell therapy combining regulatory T cells, stem cells, and conventional T cells for transplant patients; and a significant expansion of the NIH's All of Us Research Program, which now includes genomic and health data from more than 747,000 participants, over 86% of whom are from historically underrepresented groups.

Across every story, the episode underscores pharmacists' expanding responsibilities in patient counseling, safety monitoring, and care coordination as new therapies and research tools reshape clinical practice.